EU drug watchdog to consider wider use of Wegovy weight-loss drug

FRANKFURT, Jan 22 (Reuters) – The European Union’s drug regulator will this week consider wider use of Novo Nordisk’s (NOVOb.CO), opens new tab weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks.

Approval could help the Danish drugmaker better argue its case for making the drug available via public sector health systems in Europe.

The possible new use of Wegovy, based on a drug trial known as SELECT, will be assessed during the monthly meeting of a drug assessment panel of the European Medicines Agency (EMA), according to the meeting’s agenda posted on the watchdog’s website on Monday.